



Zai Lab added into the NASDAQ Biotechnology Index

2018年 12月 18日

On Dec. 14, 2018, Zai Lab (NASDAQ:ZLAB), a Shanghai-based innovative, commercial-stage biopharmaceutical company, has been selected for addition to the NASDAQ Biotechnology Index® (NASDAQ:NBI). Zai Lab's addition to the NBI will become effective prior to market open on Monday, December 24, 2018. 60 biotech stocks were added and 26 were removed for NBI re-ranking this year.

The Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB) and meet certain criteria.

The NBI is the basis for the iShares NASDAQ Biotechnology Index (SM) Fund. In addition, options based on the iShares NASDAQ Biotechnology Index Fund trade on various exchanges. For more information about the NASDAQ Biotechnology Index visit <https://indexes.nasdaqomx.com>.

About Zai Lab

Zai Lab (NASDAQ:ZLAB) is a Shanghai-based innovative, commercial-stage biopharmaceutical company focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. Zai Lab's experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates targeting the fast-growing segments of China's pharmaceutical market and addressing unmet medical needs. Zai Lab's vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its partners' and its own products in order to impact human health worldwide.